Detalhe da pesquisa
1.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood
; 142(13): 1131-1142, 2023 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363833
2.
Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia.
Vaccines (Basel)
; 11(7)2023 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37515017
3.
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Leuk Lymphoma
; 63(10): 2276-2289, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737364
4.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Lancet Haematol
; 9(3): e190-e199, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35240075
5.
Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands.
Clin Lymphoma Myeloma Leuk
; 18(1): 52-57, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29097160
6.
Prognostic factors in patients with breast cancer and malignant pleural effusion.
Breast J
; 16(6): 675-7, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21070453
7.
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma.
Hemasphere
; 4(1): e325, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32072141